The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio.
Options
BORIS DOI
Publisher DOI
PubMed ID
34996506
Description
BACKGROUND
Methotrexate (MTX) has a protective effect against cardiovascular diseases (CVD), but the mechanism is unclear.
OBJECTIVE
To investigate the effect of MTX on lipid profiles and the difference between psoriasis without arthritis (PsO) and psoriatic arthritis (PsA).
METHODS
In this prospective study, we recruited 288 psoriatic patients (136 PsA and 152 PsO) who completed 12 weeks of MTX treatment. Total cholesterol (TC), triglycerides (TG), lipoprotein A [LP(a)], high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL), apolipoprotein A1 (ApoA1), and ApoB were measured.
RESULTS
Compared with sex- and age-matched healthy controls, psoriatic patients had significantly (p < 0.0001) higher levels of proatherogenic lipids and lower levels of anti-atherogenic lipids. PsA patients had a higher ApoB/ApoA1 ratio than PsO patients (p < 0.05). Stepwise regression analysis found a positive correlation between the inflammatory marker hCRP and the Psoriasis Area Severity Index (PASI), ApoB/ApoA1 ratio, BMI, and smoking. ApoB was positively associated with concomitant arthritis, diabetes, and hypertension. MTX decreased the levels of pro-atherogenic and anti-atherogenic lipids. However, a significant reduction of the ApoB/ApoA1 ratio by MTX was only observed in male patients.
CONCLUSION
PsA patients had a significantly higher percentage of concomitant disease than PsO. The decrease of MTX on CVD might be related with sex.
TRIAL REGISTRATION
ChiCTR2000036192.
Methotrexate (MTX) has a protective effect against cardiovascular diseases (CVD), but the mechanism is unclear.
OBJECTIVE
To investigate the effect of MTX on lipid profiles and the difference between psoriasis without arthritis (PsO) and psoriatic arthritis (PsA).
METHODS
In this prospective study, we recruited 288 psoriatic patients (136 PsA and 152 PsO) who completed 12 weeks of MTX treatment. Total cholesterol (TC), triglycerides (TG), lipoprotein A [LP(a)], high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL), apolipoprotein A1 (ApoA1), and ApoB were measured.
RESULTS
Compared with sex- and age-matched healthy controls, psoriatic patients had significantly (p < 0.0001) higher levels of proatherogenic lipids and lower levels of anti-atherogenic lipids. PsA patients had a higher ApoB/ApoA1 ratio than PsO patients (p < 0.05). Stepwise regression analysis found a positive correlation between the inflammatory marker hCRP and the Psoriasis Area Severity Index (PASI), ApoB/ApoA1 ratio, BMI, and smoking. ApoB was positively associated with concomitant arthritis, diabetes, and hypertension. MTX decreased the levels of pro-atherogenic and anti-atherogenic lipids. However, a significant reduction of the ApoB/ApoA1 ratio by MTX was only observed in male patients.
CONCLUSION
PsA patients had a significantly higher percentage of concomitant disease than PsO. The decrease of MTX on CVD might be related with sex.
TRIAL REGISTRATION
ChiCTR2000036192.
Date of Publication
2022-01-07
Publication Type
Article
Subject(s)
Keyword(s)
Apolipoproteins Lipid profiles Methotrexate Psoriasis Psoriatic arthritis
Language(s)
en
Contributor(s)
Wang, Bing | |
Deng, Hui | |
Hu, Yao | |
Han, Ling | |
Huang, Qiong | |
Fang, Xu | |
Yang, Ke | |
Wu, Siyuan | |
Zheng, Zhizhong | |
Zhang, Zhenghua | |
Yan, Kexiang |
Additional Credits
Series
Arthritis research & therapy
Publisher
BioMed Central
ISSN
1478-6354
Access(Rights)
open.access